FFA
NVIV

Farther Finance Advisors’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Farther Finance Advisors’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2
Closed -$2 – 2604
2023
Q1 		$2 Hold
2
– – ﹤0.01% 2345
2022
Q4 		$5 Buy
+2
New +$5 ﹤0.01% 2176

Other funds holding NVIV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Farther Finance Advisors's NVIV Position: Q2 2023 in Review

Farther Finance Advisors sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2023, closing a stake of 2 shares — an estimated $2 sold.

Farther Finance Advisors first reported a position in NVIV in Q4 2022 and held it in 2 quarters. The position peaked at $5 in Q4 2022. 15 funds tracked by Wall St. Rank hold NVIV as of Q2 2023.

  • Farther Finance Advisors reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2023 after selling out during the quarter.
  • Farther Finance Advisors sold 2 InVivo Therapeutics Holdings Corp shares in Q2 2023, an estimated $2.
  • Farther Finance Advisors first reported a position in InVivo Therapeutics Holdings Corp in Q4 2022 and held it in 2 quarters.
  • Farther Finance Advisors's InVivo Therapeutics Holdings Corp position peaked at $5 in Q4 2022.
  • 15 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2023.

Based on Farther Finance Advisors's 13F filing for Q2 2023, filed 12 Sep 2023.